ArticleCurrent oncology (Toronto, Ont.)2013

Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.

T E Delea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.